Latest From CVRx Inc.
The PMA approval is based on the results of the BeAT HF trial, which showed that baroflex activation therapy with Barostim Neo safely improves quality-of-life scores and exercise capacity in patients with heart failure and reduced ejection fraction.
CVRx CEO Nadim Yared has moved up on the board of directors at the Medical Device Innovation Consortium as its new chair. The public-private partnership group that formed in 2012 has been effective in working with the US Food and Drug Administration to develop new regulations.
Stryker CEO Kevin Lobo says while repeal of the medical device tax is his top issue, there are four main priorities he wants to work on over the next two years as industry advocate group AdvaMed’s board chair. They include better public engagement, increased advocacy work with the new Congress, advancing new technology – especially start-ups – and increasing diversity in the medtech industry.
"All-hands-on-deck" has been the policy pursued by the US industry association AdvaMed in recent times, as it has sought to play its part in promoting user-friendly, responsive and transparent regulation and market access for medical and digital health care technology. AdvaMed chair Nadim Yared believes that, with one or two noteworthy exceptions, there is more to come in 2019 from a largely improving medtech ecosystem globally.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- CVRx Inc.
- Senior Management
Nadim Yared, Pres. & CEO
John Brintnall, CFO
Philippe Wanstok, Chief Commercial Officer
Joseph DuPay, VP, R&D & Operations
Tom Moore, VP, Market Dev.
- Contact Info
Phone: (763) 416-2840
9201 W. Broadway Ave.
Minneapolis, MN 55445
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.